Drug Approval | June 11, 2026
AstraZeneca gets CDSCO nod for Trastuzumab Deruxtecan plus Pertuzumab
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The addition of the Halcyon system represents a significant milestone in the hospital’s oncology services
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
